CHRNB4: The Potential Drug Target for Nicotine Addiction (G1143)

Target Name: CHRNB4

NCBI ID: G1143

CHRNB4

Other Name(s): cholinergic receptor, nicotinic, beta polypeptide 4 | neuronal nicotinic receptor beta 4 subunit | Nicotinic beta4 receptor | Cholinergic receptor, neuronal nicotinic, beta polypeptide-4 | Cholinergic receptor, nicotinic, beta polypeptide 4 | Neuronal nicotinic receptor beta 4 subunit | Cholinergic receptor nicotinic beta 4 subunit, transcript variant 1 | Neuronal acetylcholine receptor subunit beta-4 | Neuronal acetylcholine receptor subunit beta-4 (isoform 1) | acetylcholine receptor, nicotinic, beta 4 (neuronal) | ACHB4_HUMAN | cholinergic receptor nicotinic beta 4 subunit | Cholinergic receptor, nicotinic, beta 4 | cholinergic receptor, nicotinic, beta 4 (neuronal) | CHRNB4 variant 1

CHRNB4: The Potential Drug Target for Nicotine Addiction

Cholinergic receptor, nicotinic, beta polypeptide 4 (CHRNB4) is a transmembrane protein that plays a crucial role in nicotine addiction and other physiological processes. The CHRNB4 receptor is a potential drug target for the treatment of nicotine addiction, as it has been shown to be involved in the modulation of nicotine-induced effects on the brain.

CHRNB4 Receptor: Structure and Function

CHRNB4 is a 126-amino acid protein that consists of a pre-伪,尾, and 纬 subunits. The pre-伪 subunit contains a leucine-rich domain, which is known to play a structural role in the CHRNB4 receptor. The 尾 subunit contains a single transmembrane domain and a cytoplasmic tail, and the 纬 subunit contains a single transmembrane domain and a cytoplasmic tail that is connected to the 尾 subunit.

The CHRNB4 receptor is expressed in various tissues and cells, including the brain, heart, and lungs. It has been shown to be involved in the modulation of physiological processes, including nicotine addiction, anxiety, and stress.

CHRNB4 Receptor in Nicotine Addiction

CHRNB4 has been shown to be involved in the modulation of nicotine-induced effects on the brain. Studies have shown that CHRNB4 is activated by nicotine and that this activation is associated with the development of nicotine addiction.

One of the mechanisms through which CHRNB4 is involved in nicotine addiction is through the modulation of dopamine release in response to nicotine. Studies have shown that CHRNB4 activation leads to an increase in dopamine release in the brain, which is known to play a role in the reinforcement of nicotine use.

Another mechanism through which CHRNB4 is involved in nicotine addiction is through the modulation of neurotransmitter release in response to stress. Studies have shown that CHRNB4 activation in response to stress is associated with an increase in neurotransmitter release, including the release of cortisol and corticotropin-releasing hormone (CRH).

CHRNB4 Receptor in Other Processes

CHRNB4 is involved in various other physiological processes, including pain modulation, anxiety modulation, and neuroendocrine regulation.

Studies have shown that CHRNB4 is involved in pain modulation. CHRNB4 activation has been shown to reduce pain sensitivity in animals and to modulate pain modulation in humans.

Another study has shown that CHRNB4 is involved in anxiety modulation. CHRNB4 activation has been shown to reduce anxiety in animals and to modulate anxiety in humans.

CHRNB4 Receptor as a Drug Target

The CHRNB4 receptor is a potential drug target for the treatment of nicotine addiction and other physiological processes. Studies have shown that CHRNB4 activation is associated with the development of nicotine addiction and that this activation can be modulated by drugs.

One potential approach to targeting CHRNB4 with drugs is to use compounds that can modulate CHRNB4 function. For example, one can choose drugs that can bind to CHRNB4 and modulate its activity, such as those that can inhibit the release of neurotransmitters, reduce inflammation, or modulate the activity of other proteins that are involved in nicotine addiction.

Another approach to targeting CHRNB4 with drugs is to use compounds that can modulate CHRNB4 function in combination with other drugs. For example, a combination of a nicotine antagonist and a non-steroidal anti-inflammatory drug (NSAID) may be used to modulate CHRNB4 function and treat nicotine addiction.

Conclusion

CHRNB4 is a transmembrane protein that plays a crucial role in nicotine addiction and other physiological processes. The CHRNB4 receptor is involved in the modulation of nicotine-induced effects on the brain and is potential drug target for the treatment of nicotine addiction. Further research is needed to fully understand the role of CHRNB4 in nicotine addiction and to develop effective treatments.

Protein Name: Cholinergic Receptor Nicotinic Beta 4 Subunit

Functions: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

The "CHRNB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRNB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets